GENE ONLINE|News &
Opinion
Blog

2022-04-08| Asia-Pacific

Shionogi and Aichi Prefecture Extends Cooperation on Preventing Drug Abuse

by Joy Lin
Share To

Since 2018, Shionogi and Aichi Prefecture in Japan have been working together to raise awareness for drug abuse prevention and encourage proper use of medicines. Now, the two are extending their collaboration for one more year. 

In 2021, Shionogi and Aichi Prefecture mainly focused on hosting activities such as web seminars. These online events, held in the shadow of the COVID-19 pandemic, sought to inform residents of Aichi Prefecture on how to avoid abusing drugs and use prescription narcotics with discretion. The seminars were sponsored by the Japanese Drug Organization of Appropriate Use and Research (J-DO), an Aichi-based NPO focused on promoting the proper use of drugs, and received support from the Aichi Pharmaceutical Association and the Aichi Society of Hospital Pharmacists. 

 

Drug Abuse in Japan

 

Japan is strict with drug use. Those who take drugs such as cannabis and methamphetamine are subjected to public shaming and stigma, and may also face jail time. Yet, an increasing number of people, especially youths, are taking these drugs, helped by ease of online access. 

Drug abuse covers more than stimulants. Patients may also overdose on prescription narcotics, which have traditionally played an important role in pain management, mainly for cancer pain. 

Home medical care is increasing in the rapidly aging Japanese society, complementing the progress of community-based comprehensive care. 

Shionogi has defined “Improve social productivity and extend healthy lifespans” as one of its key issues to address. Besides promoting proper use of prescription narcotics for cancer pain relief and palliative care, the company intends to implement more initiatives with Aichi Prefecture to prevent the misuse of medicines and help those suffering from chronic pain get relief without abusing prescription drugs. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
LATEST
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
EVENT
Scroll to Top